Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
1.58M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
3.15M
-
Shares change
-
-11.5K
-
Total reported value, excl. options
-
$1.67M
-
Value change
-
-$8.06K
-
Number of buys
-
6
-
Number of sells
-
-4
-
Price
-
$0.53
Significant Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q2 2024
18 filings reported holding EVOK - Evoke Pharma, Inc. - Common Shares as of Q2 2024.
Evoke Pharma, Inc. - Common Shares (EVOK) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.15M shares
.
Largest 10 shareholders include AIGH Capital Management LLC (847K shares), Bleichroeder LP (825K shares), Altium Capital Management LP (692K shares), Nantahala Capital Management, LLC (675K shares), GEODE CAPITAL MANAGEMENT, LLC (49.7K shares), VANGUARD GROUP INC (29.9K shares), CITADEL ADVISORS LLC (11.9K shares), STATE STREET CORP (10.7K shares), Tower Research Capital LLC (TRC) (7.48K shares), and BlackRock Inc. (1.46K shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.